Asset Details
Do you wish to reserve the book?
Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
Do you wish to request the book?
Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
2024
Overview
Background
Magnetic resonance imaging (MRI) followed by targeted biopsy (TBx) is utilized for prostate cancer (PCa) detection. However, the value of adding systematic biopsies (SBx) to targeted biopsy procedures (combined biopsy; CBx) in men with suspicious MRI findings has not been determined.
Methods
We analysed biopsy outcomes in 429 men with MRI lesions in the prospective multicenter STHLM3MRI pilot study, planned for prostate biopsy. Participants underwent 1.5T biparametric MRI without contrast enhancement, reported according to the PI-RADS v2, and with TBx plus SBx if the MRI lesion score was ≥ 3. The endpoints were clinically nonsignificant (nsPCa) and clinically significant PCa (csPCa), defined as ISUP grade groups 1 and ≥ 2, respectively.
Results
The median age was 65 years (59–70), and the median PSA 6.0 ng/ml (4.1–9.0). The detection rates of csPCa when using TBx or SBx combined were 18%, 46%, and 85% in men with PIRADS scores of 3 (
n
= 195), 4 (
n
= 121), and 5 (
n
= 113), respectively. This combined strategy detected csPCa in more men than TBx alone (43.6% vs 39.2%,
p
< 0.02), with similar detection of nsPCa (19.3% vs 17.7%,
p
= 0.2).
In men with equivocal lesions (PI-RADS 3), the detection rates for csPCa were similar for the combined strategy and for TBx alone (17.9% and 15.4%,
p
= 0.06). However, there was an increase in the detection of nsPCa when using the combined strategy (21.0% vs 15.4%,
p
< 0.02).
Men with equivocal lesions and a PSA density < 0.1 ng/ml
2
or a Stockholm 3 test < 0.11 had a low risk of harboring csPCa.
Conclusions
Supplementing targeted with systematic biopsies enhances clinically significant cancer detection. However, in men with equivocal lesions, this combination has potential for detecting nonsignificant disease. A subgroup of men with equivocal MRI findings may be identified as having a low risk for significant cancer and spared unnecessary biopsies.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
